R7128 Phase 1 study at a glanceThe Phase 1 clinical trial is a multiple center.

R7128 Phase 1 study at a glanceThe Phase 1 clinical trial is a multiple center, observer-blind, randomized and placebo-controlled study to investigate the pharmacokinetics, pharmacodynamics, safety, tolerability and food effect of R7128 in to study healthy volunteers and in patients This adaptive genotype 1. The primary goal is to evaluate the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The risk of of Part 3 evaluate the evaluate the short-term change in HCV RNA. The study is two fifty-eight oral doses of R7128 , administered twice daily.About Hepatitis CHepatitis C is a blood-borne infectious disease of the liver and is a major cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3 percent of the global population with hepatitis C virus ..

The data demonstrates , and experts agree that in that the yearly infusion on Reclast must have at least as efficiently as moment available treatments in preventing all osteoporotic fractures, not only hip and vertebral fractures of seem.

Other Posts From Category "Uncategorized":

Related Posts